Fibronectin (FN1) (FN1)

Fibronectin is a high-molecular-weight glycoprotein of the extracellular matrix (ECM) that exists in both soluble plasma and insoluble cellular forms (UniProt: P02751). It plays a central role in mediating cell-to-matrix interactions by binding to integrin receptors, such as alpha-5 beta-1, primarily through its RGD (Arg-Gly-Asp) motif (PubMed: 12727312). This interaction is essential for biological processes including cell adhesion, migration, and wound healing (NCBI Gene: 2335). In disease states, fibronectin is often overexpressed; for instance, the ED-B isoform is a marker of tumor angiogenesis and is targeted by therapeutic antibodies like L19 (PubMed: 21833961). Drugs targeting fibronectin-mediated adhesion, such as Volociximab or ATN-161, aim to inhibit tumor growth and metastasis by disrupting these critical cellular attachments (PubChem: CID 11954310). Beyond oncology, fibronectin is involved in tissue fibrosis and cardiovascular repair, making it a versatile therapeutic target. However, therapeutic intervention must be carefully managed due to fibronectin's vital role in normal tissue repair and hemostasis.

Other names

FNFN1FNZCIGLETSMSFCold-insoluble globulinAnastellin

Inhibition of integrin-ligand binding, disruption of extracellular matrix assembly, and targeted delivery of therapeutic payloads to the tumor microenvironment.